GlassScriptPhysician profile
Charla Marie Phoenix
NPI 1942502992
$6,930.27
in general payments reported to CMS, 2019-2025
47 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,715 · 2022: $2,513 · 2023: $1,433 · 2024: $69.00 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,008.44 | 2021-2023 | |
| Biogen, INC. | $968.84 | 2021-2024 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $524.61 | 2021-2023 | Austedo, Austedo Xr |
| Jazz Pharmaceuticals INC. | $382.55 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $312.30 | 2021-2023 | |
| Harmony Biosciences LLC | $295.32 | 2021-2023 | Wakix |
| Amgen INC. | $263.20 | 2021-2023 | Aimovig |
| Genentech USA, INC. | $256.16 | 2021-2023 | Ocrevus |
| Biohaven Pharmaceuticals, INC. | $242.18 | 2021 | |
| Janssen Pharmaceuticals, INC | $237.54 | 2022 | |
| Alexion Pharmaceuticals, INC. | $224.69 | 2021-2023 | Ultomiris |
| Lilly USA, LLC | $194.04 | 2021-2023 | Emgality, Reyvow, Amyvid |
| Axsome Therapeutics, INC. | $166.37 | 2023-2025 | Symbravo, Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $160.65 | 2022 | |
| Ucb, INC. | $154.54 | 2021-2025 | Fintepla |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charla Phoenix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.